Quick Answer
Vivos Therapeutics, Inc. reported Shares Outstanding of 5.89 million shares for fiscal year 2024.
Vivos Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2024 | 5.89M | +221.2% |
| 2023 | 1.83M | +99.2% |
| 2022 | 920,592 | -96.0% |
| 2021 | 23.01M | +26.4% |
| 2020 | 18.21M | +46.3% |
| 2019 | 12.44M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 8.27M | +73.5% | +12.9% |
| June 30, 2025 | 7.32M | +115.3% | +24.4% |
| March 31, 2025 | 5.89M | +115.6% | +0.0% |
| December 31, 2024 | 5.89M | +221.2% | +23.6% |
| September 30, 2024 | 4.77M | +298.0% | +40.1% |
| June 30, 2024 | 3.40M | -88.6% | +24.5% |
| March 31, 2024 | 2.73M | -90.9% | +48.9% |
| December 31, 2023 | 1.83M | +99.2% | +53.2% |
- Vivos Therapeutics, Inc. showed an increase of +221.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s shares outstanding has declined by 52.7% (from 12.44 million shares to 5.89 million shares).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: